Volume 21, Issue 11 pp. 1962-1969
ORIGINAL ARTICLE

Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis - results from the CHIKARA study

Masahiro Tada

Corresponding Author

Masahiro Tada

Department of Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan

Correspondence: Dr Masahiro Tada, Orthopaedic Surgery, Osaka City General Hospital, Miyakojimahondori 2–13–22, Miyakojima-ku, Osaka 534–0021, Japan. Email: [email protected]Search for more papers by this author
Yutaro Yamada

Yutaro Yamada

Department of Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan

Search for more papers by this author
Koji Mandai

Koji Mandai

Department of Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan

Search for more papers by this author
Noriaki Hidaka

Noriaki Hidaka

Department of Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan

Search for more papers by this author
First published: 05 September 2018
Citations: 40

Abstract

Aim

Patients with rheumatoid arthritis (RA) show lower muscle mass and a higher prevalence of sarcopenia than healthy individuals. Correlations between sarcopenia and disease activity, physical function, laboratory data and body composition at baseline were investigated in a prospective, observational study (CHIKARA study) of RA patients.

Methods

Body composition was measured using a bioelectrical impedance analyzer. Parameters were compared between sarcopenia and non-sarcopenia groups, and correlations between sarcopenia and Disease Activity Score of 28 joints – erythrocyte sedimentation rate (DAS28-ESR), modified health assessment questionnaire, treatment, and laboratory data, including matrix metalloproteinase 3 (MMP3), were investigated.

Results

The participants were 100 patients with RA (women, 78%; mean age, 66.1 years). Mean disease duration was 5.5 years, DAS28-ESR was 3.55 and the prevalence of sarcopenia was 28%. Median C-reactive protein (CRP) and MMP3 were significantly higher in the sarcopenia group (0.21 mg/dL and 103.4 ng/mL) than in the non-sarcopenia group (0.11 mg/dL and 70.3 ng/mL). Sarcopenia was negatively correlated with weight, body mass index (BMI), muscle mass, body fat mass, estimated bone mass and basal metabolic rate, and positively correlated with Steinbrocker stage, CRP and MMP3 on univariate analyses. BMI, body fat mass and MMP3 were independently associated with sarcopenia on multivariate logistic regression analysis. When MMP3 was ≥ 90.7 ng/mL, the odds ratio for sarcopenia was increased 3.1-fold compared with < 90.7 ng/mL (= 0.018).

Conclusion

The prevalence of sarcopenia was 28% in patients with RA whose disease activity was mild. Low BMI, high fat mass and high MMP3 were independently associated with sarcopenia. MMP3 might be a useful marker for sarcopenia in patients with RA.

Conflict of Interest

Masahiro Tada, Yutaro Yamada, Koji Mandai and Noriaki Hidaka declare they have no conflicts of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.